Simplify Logo
Merge Labs

Merge Labs

Develops high-bandwidth brain–computer interfaces

Machine Learning Research Scientist - De Novo Design

Full-Time
$200k - $270k/yr
Senior, Expert
San Francisco, CA, USA
In Person

About the job

Requirements
  • Strong grounding in state-space models, large language models, SE(3)-equivariance, and flow matching.
  • Working knowledge of transfer-learning strategies.
  • Proficiency in Python, PyTorch, and JAX, with the ability to write clean, reproducible, production-grade code.
  • Experience bridging machine learning and experimental science while working with sparse, noisy, or high-cost data.
Responsibilities
  • Build the scientific and engineering scaffolding, in collaboration with data engineering and machine learning operations, for de novo design and closed-loop optimization, including data ingestion, machine-learning modeling, and library design.
  • Collaborate with wet-lab scientists to define tractable optimization objectives and encode domain-specific priors and constraints.
  • Prototype de novo design frameworks using internal and public datasets, and benchmark and validate model performance.
  • Integrate machine-learning models with experimental data streams and serve them to non-domain experts for model democratization.
  • Extend machine-learning frameworks to handle multi-objective or constrained optimization problems.
  • Stay up to date with the latest research in de novo design and prototype novel algorithms that can be deployed to improve discovery or development workflows.
  • Contribute to the long-term research roadmap and serve as a thought leader for scientists.
Desired Qualifications
  • Familiarity with neuroscience.

About the company

Merge Labs develops brain–computer interfaces to connect human brains with computers. Its product focus is high-bandwidth neural implants that read neural signals and transmit data to AI systems and software, enabling bidirectional communication between brain and machine. The implants are designed to work with advances in AI and neural sensing hardware, using a system of implants, interfaces, and software to interpret brain activity and control devices or software. Compared with competitors, Merge Labs aligns with Sam Altman’s vision of human–machine convergence, leveraging OpenAI ventures connections and positioning itself as a Neuralink rival with an emphasis on higher data throughput and scalable AI-assisted interpretation. The company’s goal is to create seamless, high-bandwidth brain–computer communication that enhances human capabilities and enables new ways of interacting with technology.

Company Size

11-50

Company Stage

Seed

Total Funding

$252M

Headquarters

Palo Alto, California

Founded

2025

Get referred to Merge Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Butterfly's September 1, 2026 deal creates a commercial supply chain immediately.
  • OpenAI pledged scientific foundation models and frontier tools to accelerate Merge's R&D.
  • Ultrasound BCI leverages Butterfly's 71.4% gross margin platform and semiconductor manufacturing.

What critics are saying

  • A $252 million seed round funds research, not FDA-approved products or revenue.
  • Neuralink's implant-first progress and clinical visibility threaten Merge's noninvasive positioning.
  • OpenAI's insider support invites governance scrutiny if Merge misses milestones before 2027.

What makes Merge Labs unique

  • OpenAI invested in Merge Labs' $252 million seed round at an $850 million valuation.
  • Merge Labs uses ultrasound-on-chip from Butterfly Network, unlike Neuralink's invasive electrodes.
  • Sam Altman, OpenAI, and Forest Neurotech give Merge exceptional AI and neuroscience access.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-8%

2 year growth

-8%
Yahoo Finance
Sep 3rd, 2026
Sam Altman-backed Merge Labs selects Butterfly Network as exclusive ultrasound chip supplier for brain interfaces

Merge Labs, a brain-interface startup backed by OpenAI and Sam Altman, has selected Butterfly Network as its exclusive ultrasound-on-chip supplier under a multiyear agreement. The deal includes upfront payments, development milestones, purchase commitments, access fees, and potential royalties, though specific amounts were not disclosed. Butterfly's semiconductor-based ultrasound architecture makes the system programmable and easier to embed in new devices. The company retained rights to license its technology to other partners. Butterfly's second-quarter revenue increased 39% to $32.6 million, with gross margin expanding to 71.4%. Adjusted EBITDA loss narrowed 78% to $1.4 million. Management raised full-year revenue guidance to $119 million to $123 million. Thirty-three hedge funds held Butterfly Network in the second quarter, up from 26 in the first quarter.

Florida Today
Feb 14th, 2026
OpenAI invests in Merge Labs at $850M valuation

OpenAI has invested in Merge Labs at an $850 million valuation, according to reports. The investment focuses on scalable AI backends, including AICC technology. Details about the funding round, including the investment amount and other participants, were not disclosed. The partnership appears aimed at advancing AI infrastructure and backend capabilities. Merge Labs is working on developing scalable systems to support AI applications. The company's technology is designed to handle the computational demands of modern AI models. The investment represents OpenAI's continued expansion beyond its core business into supporting technologies and infrastructure for artificial intelligence development.

TechCrunch
Jan 16th, 2026
OpenAI invests in Sam Altman’s brain computer interface startup Merge Labs | TechCrunch

Merge Labs is a “research lab” dedicated to “bridging biological and artificial intelligence to maximize human ability.” OpenAI wrote the largest check in Merge Labs' $250 million seed round at an $850 million valuation.

Bloomberg Law
Jan 15th, 2026
Sam Altman's Merge raises $252M to connect human brains to computers

Merge Labs, co-founded by AI billionaire Sam Altman, has raised $252 million to develop devices connecting human brains to computers. The company aims to seamlessly link people and artificial intelligence to "maximise human ability, agency, and experience". The funding reflects growing Silicon Valley interest in brain-computer interfaces as entrepreneurs anticipate a future where AI becomes so advanced that humans may need to augment their brains to keep pace. Similar to how smartphones provide digital access, experimental brain technology is being designed to streamline human interaction with AI systems. The investment underscores the increasing focus on neurotechnology as a key frontier in the race to integrate artificial intelligence into human capabilities.

Wired
Dec 19th, 2025
Sam Altman’s New Brain Venture, Merge Labs, Will Spin Out of a Nonprofit

Merge Labs, a brain-computer interface startup that seeks to read brain activity using ultrasound, is being spun out of Forest Neurotech, a Los Angeles nonprofit.